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A B S T R A C T
Patients with cardiovascular disease show autonomic dysfunction, including sympathetic activation and
vagal withdrawal, which leads to fatal events. This review aims to place sympathovagal balance as an
essential element to be considered in management for cardiovascular disease patients who beneﬁt from
a cardiac rehabilitation program. Many studies showed that exercise training, as non-pharmacologic
treatment, plays an important role in enhancing sympathovagal balance and could normalize levels of
markers of sympathetic ﬂow measured by microneurography, heart rate variability or plasma
catecholamine levels. This alteration positively affects prognosis with cardiovascular disease. In general,
cardiac rehabilitation programs include moderate-intensity and continuous aerobic exercise. Other
forms of activities such as high-intensity interval training, breathing exercises, relaxation and
transcutaneous electrical stimulation can improve sympathovagal balance and should be implemented
in cardiac rehabilitation programs. Currently, the exercise training programs in cardiac rehabilitation are
individualized to optimize health outcomes. The sports science concept of the heart rate variability
(HRV)-vagal index used to manage exercise sessions (for a goal of performance) could be implemented in
cardiac rehabilitation to improve cardiovascular ﬁtness and autonomic nervous system function.
 2016 Elsevier Masson SAS. All rights reserved.
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According to recent epidemiological studies, cardiovascular
disease (CVD) is the most common cause of death among
Europeans: more than 4 million people die of CVD every year in
Europe (45% of all deaths) [1,2]. Disorders of the autonomic
nervous system (ANS) have a key pathophysiological role in early
stages of essential hypertension [3,4], myocardial infarction [5,6],
and chronic heart failure (CHF) [7–10], producing coronary
vasoconstriction, increasing cardiac oxygen consumption and
leading to fatal events [11–13]. The clinical importance and
prognostic implications of the exaggerated sympathetic nervous
system (SNS) are well documented in CVD [14,15] in that it is a
known trigger of cardiac arrhythmias and sudden death [16–19].
The activity of the central nervous system also seems to play a role* Corresponding author at: Clinic of Saint-Orens, 12, avenue de Revel, 31650
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humoral overactivity of the renin–angiotensin–aldosterone system
(RAAS) [9,22]. In the long term, sympathetic chronic stimulation is
deleterious [14,23]. In the periphery, tubular ﬂuid level and sodium
reabsorption increase in response to RAAS activation [24] and
peripheral arterial resistance increases [25], thereby increasing
cardiac pre- and postload. In addition, sympathetic hyperactivity
alters myocardial calcium cycling, which is responsible for reduced
myocardial contractility [26]. The spontaneous activity of certain
slow calcium channels (L-type) could explain in part ventricular
arrhythmias and cardiac sudden death [17].
Pharmacological treatments for CVD need to decrease the
overactivity of the SNS (b blockers, angiotensin-converting
enzyme inhibitors, etc.) [27,28] and to increase the activity of
the parasympathetic nervous system (adenosine, cholinesterase
inhibitors, statins) [29]. Additionally, different non-pharmacologi-
cal techniques have the same goal, such as vagal stimulation, renal
denervation and carotid baroreceptor stimulation, and were
well described in a recent review [30]. Among the non-
pharmacological techniques, ET is of growing interest in major
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recommendations from the European Society of Cardiology and an
IB level from the American Heart Association, ET has become one of
the pillars of CHF treatment and coronary heart disease (CHD) [31–
35]. The therapeutic potential of restoring or enhancing the cardiac
vegetative balance with ET is very promising [36–38], but the
underlying mechanisms are still unclear.
This review aims to summarize some of the beneﬁcial effects of
aerobic ET on CVD and place sympathovagal balance as an essential
element to be considered in management for patients who beneﬁt
from a cardiac rehabilitation program.
2. Effect of ET on the autonomic nervous system
2.1. Muscle sympathetic nerve activity
Muscle sympathetic nerve activity (MSNA) is a neurophysio-
logical method (microneurography) that allows for recording
sympathetic nerve trafﬁc. MSNA is markedly increased in patients
with CHD [39,40] (45  2.3 vs. 31  1 bursts/min; p < 0.001),
hypertension [41,42] (33.3  1.7 vs. 23.9  1.6 bursts/min;
p < 0.01 respectively), and CHF [43] (62  4 vs. 39  4 bursts/min;
p < 0.01) as compared with healthy subjects, but MSNA can be
decreased by ET [44,45]. The research team from the Heart Institute of
University of Sao Paulo has spent more than 10 years investigating the
effects of ET on MSNA in CHF and CHD patients [46–51]. The team
demonstrated that regular ET can normalize the basal overactivationTable 1
Effect of exercise training on muscle sympathetic nerve activity (MSNA) in patients with
literature.
References No. of
patients
Patient characteristics Training prot
CHF patients
Antunes-Correa,
2012
52 45–59 years
Trained (n = 16) vs. untrained
(n = 17)
60–75 years
Trained (n = 11) vs. untrained
(n = 8)
4 months 3 
Stretching
Cycling
Strengthenin
Intensity: ana
threshold up
the respirato
point
Antunes-Correa,
2010
40 57–60 years
Men exercise-trained (n = 12)
Men untrained (n = 10)
Women exercise-trained
(n = 9)
Women untrained (n = 9)
Roveda, 2003 16 35–60 years
Exercise-trained (n = 7)
Sedentary control (n = 9)
Fraga, 2007 27 Exercise training (n = 15)
Untrained control (n = 12)
Mello Franco,
2006
29 Untrained control (n = 12)
Exercise trained (n = 17)
Post-ACS patients
Martinez, 2011 28 Exercise trained (n = 14)
Untrained control (n = 14)
6 months/3 
Stretching/cy
strengthening
thresholdof the sympathetic nerve (Table 1). After 4–6 months of ET
(3 supervised 60-min exercise sessions/week of cycling and
strengthening), baseline values of MSNA (about 45 bursts/min for
CHF patients) decreased signiﬁcantly to within normal values relative
to healthy participants (about 30 bursts/min) [46–51], with no
change in untrained groups. Furthermore, ET had no gender- or age-
speciﬁc effect on MSNA.
2.2. Heart rate variability (HRV)
HRV is a non-invasive reproducible measure of ANS function
corresponding to the balance between sympathetic and parasym-
pathetic effects on the sinoatrial node rate [52–54]. HRV indexes
are highly decreased in CVD patients and predict poorer outcomes,
such as reduced left-ventricular function and sudden cardiac death
[38,55–58]. The risk of all-cause and progressive heart failure
death was increased with a standard deviation of normal to normal
R-R intervals (SDNN) of <67 ms (relative risk [RR] 2.5; 95% CI 1.5–
4.2) [56]. In a retrospective analysis of 1284 CHD patients, SDNN
values <70 ms signiﬁcantly and independently predicted cardiac
mortality (RR 3.2; 95% CI 1.6–6.3) [59]. According to Bilchick et al.
[58], each increase of 10 ms in SDNN conferred a 20% decrease in
risk of mortality (p = 0.0001) with an increase in vagal tone and a
decrease in sympathetic activity [38,60–65]. In a recent random-
ized controlled, single-blinded trial, Murad et al. [64] included
66 CHF patients (mean age 69 years, New York Heart Association
[NYHA] class II–III) with preserved or reduced ejection fraction. chronic heart failure (CHF) and post-acute coronary syndrome (post-ACS) from the
ocol MSNA basal values MSNA post-training values
 60 min/week
g
erobic
 to 10% below
ry compensation
43–50 bursts/min
according to the
group with no
difference between
them
In trained groups: 27–29
bursts/min (p < 0.001)
Unchanged in untrained
groups
No age effect (p = 0.69)
43–50 bursts/min
according to the
group with no
difference between
them
In trained groups: 30 bursts/
min (p < 0.001)
Unchanged in untrained
groups
No gender effect
40–50 bursts/min In reply to: trained groups 30
bursts/min (p < 0.001)
Unchanged in untrained
groups
HF trained group did not differ
from trained healthy control
group after training
45 bursts/min In trained group: 35 bursts/
min (p = 0.001)
Unchanged in untrained
groups
43–45 bursts/min In trained group: 35 bursts/
min (p = 0.007)
Unchanged in untrained
groups
 60 min/week
cling/
/anaerobic
42–45 bursts/min In trained group: 20 bursts/
min (p < 0.001)
(similar to healthy control
group)
Unchanged in untrained
groups
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signiﬁcantly greater increase in both SDNN and root mean square
successive difference (a time domain measure of heart period
variability) as compared to controls (+15.46 vs. +2.37 ms, p = 0.016,
and +17.53 vs. +1.69 ms, p = 0.003, respectively). This ﬁnding may
indicate a favorable effect of ET on prognosis for CHF patients.
Larsen et al. [63] evaluated the correlation between HRV index and
survival. For this, 12 CHF patients (mean age 67 years; NYHA class
III) underwent a 12-week rehabilitation program. After 87 months
of follow-up, survivors and non-survivors showed borderline
signiﬁcant differences in temporal variables of HRV after training
(+10.4  8.45 vs. 2.7  10.2 ms, p = 0.053). Only survivors showed
a signiﬁcant increase in SDANN-i after ET (107.9  40.6 vs.
118.3  48.1 ms, p = 0.029). In CHD patients, the results were
heterogeneous and the resting HRV index often remained unchanged
after the cardiac rehabilitation program. For example, Duru et al. [66]
found unchanged basal HRV indexes after 8 weeks of aerobic exercise
(at 70% of HR reserve) in 25 patients with post-acute coronary
syndrome (post-ACS). La Rovere et al. [67] studied HRV indexes in
22 trained and untrained CHD patients by the head-up tilt test.
Frequency domain HRV indexes at rest were not changed after a
4-week training program. Nevertheless, during the head-up tilt test,
trained patients showed signiﬁcantly greater increases in low-
frequency power (LFnu) (84  3% vs. 69  5%) and decreases in
high-frequency power (HFnu) (7  1% vs. 19  4%) than controls.
With orthostatic stress (such as a tilt test), the baroreceptors are
stimulated to drive an increase in sympathetic vasoconstrictor
outﬂow and a reduction in vagal tone. Therefore, in post-ACS trained
patients, the reﬂex activity of the autonomic pathways may have been
improved. Of note, the HRV index could be improved early in post-
ACS patients with ET. In a very short ET program, 5 days, in phase I
cardiac rehabilitation, Santos-Hiss et al. [68] highlighted that trained
patients in the resting position showed increased HFnu after training
(35.9%  19.5% to 65.19%  25.4%, p = 0.002) and decreased LFnu
(58.9%  21.4% to 32.5%  24.1%, p = 0.024) and LF/HF ratio
(3.12  4.0 to 1.0  1.5, p = 0.004), with no changes in controls.
2.3. Arterial baroreﬂex function
Arterial baroreceptors (located in the aortic arch and carotid
sinuses) are the starting point of nervous afferences playing a
constant inhibitory role in decreasing SNS activity [69–71]. De-
fective arterial baroreﬂex is well known to contribute to
sympathetic overactivity [9,72–75]. The studies of La Rovere
et al. underlined that arterial baroreﬂex is a powerful predictor of
cardiovascular death, with <3.0 ms/mmHg associated with
increased risk of cardiac mortality, by 2.8-fold (95% CI 1.24–
6.16) [74,76]. Several mechanisms could explain this impairment:
reduced sensitivity of the baroreceptor afferent ﬁbers [77–79]
mediated in part by reduced expression and activation of the
voltage-gated sodium channels [80] and in part by elevated
plasma aldosterone content, which reduces afferent discharge
sensitivity [81], and deterioration of the central autonomic
pathways that mediate the baroreﬂex [82,83]. Baroreﬂex function
is improved with ET in animal studies [84–86]. In CHF patients, ET
seems to improve arterial baroreﬂex function [65,87] or prevent
its deterioration [88]. In 12 patients with CHF (mean age 58 years,
left-ventricular ejection fraction 36%, NYHA class II-III), Pietila
et al. studied the effects on baroreﬂex sensitivity (among other
things) of a 6-month ET protocol comprising light-intensity circuit
muscle training and aerobic cycling once a day for 6 days/week. At
the end of the program, baroreﬂex sensitivity increased by 74%,
from 5.83  0.82 to 10.15  1.66 ms/mmHg (p < 0.05). The most
recent study investigating the effect of ET on the arterial baroreﬂex
control of MSNA (ABRMSNA) in CHF was conducted by the Heart
Institute of the University of Sao Paulo [89]. The authors studied theimpact of 4 months of exercise on the magnitude and latency of the
arterial baroreﬂex response. For this, 26 CHF patients (NYHA class II-
III, left-ventricular ejection fraction 40%) were randomized to
undergo no training or an ET program. The ET protocol was in line
with the group’s other studies (4 months, 60 min/day, 3 times/
week). The gain and time delay of ABRMSNA were unchanged with
training, and with no training, the baseline values worsened at
4-month follow-up (gain and time delay values of ABRMSNA before
and after the 4-month follow with no training were 3.5  0.7 vs.
1.8  0.2, a.u./mmHg, p = 0.04, and 4.6  0.8 vs. 7.9  1.0 s, p = 0.05,
respectively). The authors concluded that the reduced sympathetic
nerve activity was mediated by an increase in arterial baroreﬂex
sensitivity but also may be modulated by chemoreﬂex control and/or
ergoreﬂex control.
In the same way, baroreﬂex gain was decreased after
myocardial infarction. In 2011, Martinez et al. [51] showed that
at 3 months after ACS (2 months of ET), baroreﬂex control
increased from 6.0 to 15.6 ms/mmHg with ET. This beneﬁt was
even greater at 7 months after ACS (6 months of ET), when
baroreﬂex control in this group was 18.5 ms/mmHg and similar to
that in healthy controls (16.4 ms/mmHg). Untrained post-ACS
patients did not show any improvement in the baroreﬂex
sensitivity variable during 7 months of follow-up, despite the
same clinical management. In this context, ET based on 3 times/
week for 6 months restored baroreﬂex sensitivity in patients with
myocardial infarction, for a long-term protective effect of ET in
these patients.
2.4. Resting HR and HR recovery
Epidemiological studies have conﬁrmed that an elevated
resting HR reﬂects greater neurohormonal activation and is an
independent predictor of cardiovascular and overall mortality in
the general population and in patients with CVD [90–96]. In
addition, a high resting HR affects ischemic episodes that may
trigger arrhythmias [93,97]. Lowering the HR to about 60 beats/
min [98] with pharmacological treatments reduced overall and
cardiovascular-related mortality [93,97,99,100]. ET in patients
with CVD appears to be efﬁcient in lowering resting HR and
increasing chronotropic reserve [101–103]. For example, after a 2-
month residential rehabilitation program, resting HR decreased by
11 beats/min in a CHF exercise group [104]. HR recovery after a
maximal exercise stress test is considered a vagal tone indicator.
The increase in HR is ﬁrst due to withdrawal of parasympathetic
activity with lower intensity, then, with moderate and high
intensity, is due to a sympathetic activation [53]. Just after peak
exercise, HR drops during the ﬁrst seconds and minutes because of
parasympathetic reactivation with the decrease, then sympathetic
inactivation [53]. HR recovery is considered an indicator of vagal
tone [105] and a strong prognostic factor of cardiovascular events
and death in healthy people and CHF patients [91,101,104,106,
107] as well as patients with coronary artery disease
[106,108,109]. In CHF, HR recovery is altered, with parasympa-
thetic and baroreﬂex dysfunction [110,111]. Nonetheless, ET
studies reported improvements in HR recovery [104,112] in
patients with CHF and CHD [113,114]. In 2007, Myers et al.
[104] showed that HR recovery was signiﬁcantly faster in the
exercise group from minutes 2 to 6 after a 8-week training program
as compared to the sedentary control group (ANOVA main effect in
trained subjects 12.6 beats/min, p < 0.001; main effect among
controls 2.6 beats/min, p = 0.27; between-group interaction
p = 0.005). Resting HR and HR recovery were enhanced with an
ET, presumably because of impaired vagal tone [115]. In conse-
quence, with a lower resting HR and a better HR recovery after
exercise, HR reserve is increased, for better sympathovagal balance
and improved survival for patients with CVD.
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ANS
The physiological mechanisms contributing to improved
sympathovagal balance are multiple and have not yet been fully
deﬁned. Many studies have investigated changes in plasma
catecholamine levels after ET programs in CHF and have shown
encouraging results, with a decrease in levels at rest and during
submaximal exercise [103,116]. Recently, Rengo et al. [103]
investigated the impact of a 3-month ET program on changes in
plasma level of norepinephrine, serum level of N-terminal pro-
brain natriuretic peptide and mortality over a mean follow-up of
27 months. The authors enrolled 221 CHF patients (mean age
72 years, mean left ventricular ejection fraction 32%). The 3-month
training protocol (30 min of cycling 3 times/week at 60–70% peak
VO2) decreased plasma norepinephrine level (642–578 pg/mL,
p < 0.0001), N-terminal proBNP level (2111–1532 pg/mL,
p < 0.0001), and HR (83.6–69.2 bpm, p < 0.0001). Change in
resting plasma norepinephrine level was the most powerful
predictor of cardiac mortality at 27-month follow-up (hazard
ratio 38.7, p < 0.0001). Furthermore, when the authors stratiﬁed
patients by median values of Dnorepinephrine level (% changes),
mortality rate was higher for patients with Dnorepinephrine level
below than above the median (87% vs. 4%). Furthermore, ET
induced neuromodulation in both the peripheral and central levels.
Patel et al. investigated how ET could normalize the central
sympathetic outﬂow in rats with heart failure. Their results
suggested a positive central modulation in the inhibitory and
excitatory pathways (for details, see review [117,118]) via
increased nitric oxide level in the paraventricular nucleus and
reduced central angiotensin II level that contributed to sympatho-
inhibition and sympatho-excitatory paths, respectively, in brain
areas [119]. Aerobic ET in CHF and in hypertensive rats could be
efﬁcient as renin–angiotensin system blocker therapy to reduce
the brain renin–angiotensin system activity and to decrease
arterial pressure as well as sympathetic overactivity [120,121].
4. Alternative interventions to traditional ET
Most studies investigating the effects of ET on ANS activity in
CVD are based on continuous moderate aerobic exercise. Little is
known about the effects of high-intensity interval training
combined or not with other activities such as relaxation and
breathing exercises or electrical stimulation. In this section, we
discuss the importance of these different types of activities and
their positive effect on the sympathovagal balance.
4.1. High-intensity interval training (HIIT)
The latest recommendations suggest interval training (IT) for
heart failure patients [122–124] and CHD [125]. HIIT is deﬁned
as repeated short-intensity bouts (e.g., 30–60 s at 90–100% peak
exercise capacity) interspersed with a recovery period (30–120 s
at 50% peak exercise capacity or passive recovery). HIIT may be
more effective than moderate intensity and continuous exercise
(MICE) for improving exercise capacity, quality of life, maximal
oxygen consumption (VO2max) and cardiac remodeling in CHD
and CHF patients [126–128]. In a recent review [129] of HIIT in
cardiac rehabilitation programs (phase II and III), Gayda et al.
discussed the interest of developing progressive models of
ET based on HIIT combined with other forms of exercise
sessions such as MICE, resistance training or inspiratory muscle
training.
In healthy subjects, ANS responses differ by exercise modality
(duration, frequency, intensity, recovery, volume). Therefore, our
team studied an optimized and safe HIIT model [130–132]. In 2013[133], we studied the effect of one session of HIIT on ANS activity
while ensuring security and patient comfort [130]. Our hypothesis
was that HIIT would enhance vagal tone and thus reduce the
likelihood of arrhythmic events in CHF. Eighteen CHF patients
underwent a baseline assessment (control condition) and were
randomized to a single session of HIIT (repeated 30 s of exercise at
100% peak power alternating with phases of 30 s of passive
recovery) and to isocaloric MICE. As compared to control and MICE
conditions, a single session of HIIT signiﬁcantly increased
parasympathetic tone. The normalized HF power measured by
24-h electrocardiography for the 3 conditions was 31.56%, 24.61%
and 35.95%, respectively (p < 0.01). After HIIT, the number of
premature ventricular contractions decreased signiﬁcantly
(531 vs. 1007 and 1671 for control and MICE, respectively,
p < 0.01). We found a correlation between changes in premature
ventricular contraction and LF/HF ratio (r = 0.66, p < 0.01) in
patients exposed to HIIT. Passive recovery with each 30 s may have
led to ‘‘a vagal training stimulation’’ and the beneﬁcial effects on
HRV and PVC are probably related to this speciﬁc mode of HIIT,
which suggests sympathovagal balance resetting in the postexer-
cise period. The clinical importance of premature ventricular
contractions (and HRV) in CHF is a powerful predictor of
cardiovascular mortality [134]. Furthermore, according to patients,
HIIT was the most preferred protocol, associated with lower
perceived exertion as compared with MICE, and no adverse event
was reported by health care providers or patients. Other studies
reported improvements in HRV after HIIT in cardiac patients [135]
and in patients with type 2 diabetes mellitus [136]. However, the
study of Currie et al. [137] reported no improvement in HRV index
and HR recovery in CHD patients after a 12-week ET of HIIT or MICE
despite an increase in VO2peak in the 2 groups (+20% p < 0.001, with
no difference between them). The authors suggested that the
length of recovery between ACS and the beginning of training (5–6
months), the optimal medical management, and the normative
baseline values contributed to this lack of signiﬁcant change in
autonomic nervous activity.
These results highlight the positive beneﬁt–risk ratio associated
with HIIT and suggest that this type of intervention could reduce
the cardiovascular risk. Nevertheless, the long-term effects of HIIT
remain to be studied.
4.2. Breathing exercises or relaxation
Respiratory sinus arrhythmia–biofeedback or heart rate
variability–biofeedback involves the lowering of the breathing
rate to the frequency at which the amplitude of HRV is maximized.
This breathing exercise stimulates the baroreceptor [138,139],
thereby modulating the sinus rhythm to enhance sympathovagal
balance and cardiovascular risk factors [140], including in CVD
[139,141, 142]. In the Bernardi et al. study [142], 81 patients with
CHF and 21 healthy controls underwent electrocardiography,
respiration, and blood pressure measurement during 5 min of
spontaneous breathing, 4 min of controlled breathing at
15 breaths/min (corresponding to spontaneous breathing) and
4 min of controlled breathing at 6 breaths/min. The slow breathing
rate in the CHF group increased the mean RR interval to 20 ms,
decreased both systolic and diastolic blood pressure (systolic, from
117 to 110 mmHg, p < 0.009; diastolic, from 62 to 59 mmHg,
p < 0.02) and signiﬁcantly increased the baroreﬂex sensitivity
(from 5.0 to 6.1 ms/mmHg, p < 0.0025). The recent ﬁrst systematic
review of the effect of relaxation and meditation on symptom
management strategies in CHF [143] found symptom-related
quality of life improved with this approach, as well as pain,
dyspnea, fatigue, and sleep disturbance.
Breathing techniques, relaxation exercises or some types of
meditation have a favorable impact on parasympathetic and
F. Besnier et al. / Annals of Physical and Rehabilitation Medicine 60 (2017) 27–35 31sympathetic activity (for review [144]), with increased HF
power and decreased LF/HF ratio. In the Curiati et al. study
[145], 19 older patients with optimally treated CHF were
randomized into 2 groups: a meditation group (who listened to a
30-min audiotape twice a day for 12 weeks and attended a
weekly meeting) or a control group (who just attended a weekly
meeting). Norepinephrine level was reduced in the meditation
group alone (from 677.7 to 387.1 pg/mL, p = 0.008), which
suggests reduced SNS activity, and were unchanged in the
control group.
4.3. Transcutaneous electrical nerve stimulation (TENS)
TENS is classically used to stimulate large myelinated afferent
ﬁbers, used in pain treatment, whereas neuromuscular electrical
stimulation (NMES) stimulates efferent ﬁbers, causing muscular
contraction. For the ﬁrst time, our group provided evidence that
TENS could directly reduce sympathetic activity (measured by
MSNA) in patients with CHF in a randomized, sham-controlled,
double-blind study (EMSICA Study [146]). We recruited 22 CHF
patients (NYHA class III): 11 underwent TENS, and 11 NMES.
Each of the protocols was cross-over, randomized and sham-
controlled. MSNA was recorded immediately after electrical
stimulation cessation on the opposite stimulated limb. Com-
pared to sham stimulation, both TENS and NMES reduced MSNA
(69.7 vs. 63.5 bursts/min, p < 0.01 after TENS and 56.7 vs.
51.6 bursts/min, p < 0.01 after NMES). These ﬁndings highlight
the clinical importance of this non-pharmacological therapy
based on ET for long-term treatment of patients with myocardial
infarction. Reduced MSNA by TENS could be attributable to
enhanced spontaneous baroreﬂex sensitivity; As well, the
ergoreﬂex induced by TENS could stimulate the nucleus tractus
solitarius and the release of substance P, which could interact
with baroreﬂex sensitivity and decreased sympathetic outﬂow
[147].Fig. 1. A decision tree for prescribing exercise according to heart rate variability (HRV) ind
training (ET) sessions are set at low intensity and increase gradually to moderate inten
indexes (high-frequency [HF] power and ratio of low-frequency [LF] to HF). The ﬁrst reﬂe
increase or remain stable (HRV+), the training intensity increases; when HRV indexes dec
scale [154]) must also be considered. LI: low intensity; MI: moderate intensity; HIIT: h
decrease in LF/HF ratio; HRV is deﬁned as a decrease in HF power and an increase in5. Perspectives
Several reports support evidence for an association between
parasympathetic factors and training level [148,149]. These data
are available for trained people or athletes but not patients with
CVD. In the ﬁeld of high sport performance, ET programs are
individualized to optimize physiological adaptations (e.g., VO2max,
metabolic or cardiac recovery) and consider physiological varia-
bles related to the athletes. With this in mind, some authors have
proposed that outcomes of cardiac ANS activity would be an
efﬁcient tool for individualized training prescription and induced
long-term physiological beneﬁt [149–151]. In view of this
suggestion, an interesting review by Stanley et al. [149]
recommended that training (not only for highly trained but also
inactive people) could be structured with weekly micro-cycles to
improve cardiovascular ﬁtness or cardiac recovery or induce an
overload of training to progress ﬁtness. For example, to maximize
recovery, the period of rest and low-intensity training sessions are
increased and the frequency of high-intensity training sessions is
reduced, each separated by at least 48 h of recovery to allow for
beneﬁcial compensation of the cardiovascular and autonomic
systems. While improving cardiovascular ﬁtness, the weekly
micro-cycle is structured with consecutive high and moderate
intensity training followed by a rest day to induce improvement. In
our clinical experience, all patients perform the same daily ET
session to a target HR corresponding to 70% of HR reserve 5 beats/
min. Sometimes, high-intensity interval training is used (but this
mode is not systematized and depends on physiotherapist practice).
Adapting the recommendations of Stanley et al. (2013) would be of
interest to investigate the effect of an individualized ET program
based on HRV outcome as previously described.
In CHF, one study [152] found lower pre-training HRV index
associated with less improvement in physical capacity after a
cardiac rehabilitation program. In this observational, non-random-
ized study, 57 CHF patients (left ventricular ejection fraction <35%)exes in cardiac patients. During the ﬁrst week of cardiac rehabilitation, the exercise
sity. From the second week, the exercise intensity is prescribed according to HRV
cts effects on vagal tone and the second, sympathovagal balance. When HRV indexes
rease (HRV), the training intensity decreases. The rate of perceived exertion (Borg
igh intensity interval training. HRV+ is deﬁned as an increase in HF power and a
 LF/HF ratio.
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exercise test before and after 2 weeks of training; HRV was
evaluated by 24-h-electrocardiography–Holter recordings. Accord-
ing to pre-training SDNN values, patients in the ﬁrst quartile (55 ms)
showed a signiﬁcantly lower VO2 peak (11.4 ml/min/kg) that those
with higher SDNN values (>16 ml/min/kg) (p = 0.015). The authors
concluded that the pre-training HRV index could help identify
patients who need speciﬁc individualized training to improve
cardiovascular capacity. In other words, the HRV index could be
helpful to distinguish ‘‘responders’’ and ‘‘non-responders’’ to an ET
program, with more attention to the ﬁrst type. With the concept of a
weekly micro-cycle described by Stanley et al., patients could
beneﬁt from a session of HIIT or low intensity, or rest, depending on
their HRV values.
In healthy males, Kiviniemi et al. [153] investigated a 4-week
endurance ET program based on daily HRV index. Participants were
randomized to a predeﬁned training group (n = 8), an HRV guided
training group (HRV, n = 9) or a control group (n = 9). With a
maximum of 2 consecutive high-intensity sessions or resting
sessions, the daily training sessions of the HRV group were guided
by a daily morning measurement of the HRV index for 10 min. If
HFnu did not change or was increased (as compare to individual
reference values), the training session was set at high intensity, and
if HFnu was decreased signiﬁcantly, low-intensity training or
resting was prescribed (Fig. 1). After the 4-week training, VO2max
increased only in the HRV group (+4 ml/min/kg, p = 0.002). The
authors concluded that daily HRV measurements may help
determine the type of exercise session (low or high intensity or
rest) based on the status of autonomic regulation. Knowing that
cardiac patients present wide heterogeneity in response during
cardiac rehabilitation (revealing even negative changes or non-
response), this easy-to-use tool would be useful for daily training
prescription and supervision during cardiac rehabilitation. On the
basis of the ‘‘HRV guided training group’’ of Kiviniemi et al., we
propose a decision tree to prescribe exercise based on HRV in
cardiac patients (Fig. 1). Indeed, this model remains theoretical and
has not been tested in cardiac patients.
In cardiac rehabilitation centers, the optimal ET program to
improve clinical values must consider individual characteristics of
patients; exercise prescribers should be adequately trained to
adapt the features of physical exercise sessions to each patient
according to their needs, desires and physiological values.
In this context, the use of HRV has become an approach to
fatigue well inspired by the concept derived from sports science,
which uses the HRV-vagal index to manage exercise sessions. To
monitor patients on Monday (after the weekend), a valid score
must consider the medication, sleep quality, blood pressure and
other factors associated with HRV. This score could guide the
exercise prescribers who anticipate an overload of exercise
resulting in fatigue or otherwise detecting the possibility of
increasing the safe workload.
6. Conclusions
Overall, ET, associated with other non-pharmacological strate-
gies, may positively affect the ANS by increasing vagal modulation
and decreasing sympathetic tone. Further research is needed to
identify the exercise regimen (i.e., duration and intensity) that
produces optimal improvements in HRV. Furthermore, the use of
HRV indexes to prescribe, monitor and supervise the ET of patients
referred to a cardiac rehabilitation program should be proven and
established.
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